Coverage
-
January 28, 2013
The Federal Circuit on Monday ruled in favor of specialty pharmaceutical company Allergan Inc., affirming a district court's ruling that two generic-drug makers would infringe on Allergan's patent if they continued plans to manufacture a generic version of glaucoma drug Lumigan.
1 other articles on this case.
View all »